Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

First Posted Date
2003-09-11
Last Posted Date
2013-09-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
18
Registration Number
NCT00068315
Locations
🇺🇸

Mercy Medical Center, Canton, Ohio, United States

🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

🇺🇸

Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 4 locations

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

First Posted Date
2003-08-07
Last Posted Date
2013-02-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00066625
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2003-08-07
Last Posted Date
2013-01-08
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
7
Registration Number
NCT00066508
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

First Posted Date
2003-08-07
Last Posted Date
2015-07-23
Lead Sponsor
University Health Network, Toronto
Registration Number
NCT00066352
Locations
🇨🇦

Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada

🇺🇸

Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States

🇨🇦

Princess Margaret Hospital, Toronto, Ontario, Canada

and more 12 locations

A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Phase 3
Completed
Conditions
Multiple Myeloma
First Posted Date
2003-07-11
Last Posted Date
2012-01-13
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
600
Registration Number
NCT00063726
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Texas Oncology at Medical City Dallas Hospital, Dallas, Texas, United States

🇺🇸

Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States

and more 73 locations

Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Interventions
Drug: bortezomib
Drug: docetaxel
First Posted Date
2003-07-09
Last Posted Date
2019-12-13
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
4
Registration Number
NCT00064012
Locations
🇺🇸

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States

🇺🇸

Siteman Cancer Center, Saint Louis, Missouri, United States

🇺🇸

St. Louis University Hospital Cancer Center, Saint Louis, Missouri, United States

and more 18 locations

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

First Posted Date
2003-07-08
Last Posted Date
2007-02-14
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Registration Number
NCT00063791
Locations
🇺🇸

Henry Ford Health System, Detroit, Michigan, United States

🇺🇸

Michael Meshad, Oncology Center, Mobile, Alabama, United States

🇺🇸

Toledo Clinic, Toledo, Ohio, United States

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

First Posted Date
2003-06-06
Last Posted Date
2021-02-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
41
Registration Number
NCT00061932
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

First Posted Date
2003-04-09
Last Posted Date
2013-06-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
45
Registration Number
NCT00030368
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

First Posted Date
2003-02-06
Last Posted Date
2013-05-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
69
Registration Number
NCT00054483
Locations
🇺🇸

University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy